Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy With Oncolytic HSV-1 M002

Molecular Therapy - Oncolytics - United Kingdom
doi 10.1016/j.omto.2017.09.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

Current Pharmaceutical Biotechnology
BiotechnologyPharmaceutical Science
2012English

Oncolytic Virotherapy

Nature Biotechnology
Applied MicrobiologyBiotechnologyBiomedical EngineeringMolecular MedicineBioengineering
2012English

Targeting Pediatric Cancer Stem Cells With Oncolytic Virotherapy

Pediatric Research
Child HealthPediatricsPerinatology
2012English

Delivery and Biosafety of Oncolytic Virotherapy

Frontiers in Oncology
Cancer ResearchOncology
2020English

Undifferentiated Pleomorphic Sarcoma

2020English

412. The Efficacy and Bio-Distribution of Oncolytic HSV-1 (G47Δ) in Mouse Orthotopic Esophageal Cancer Models

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy

Cancer immunology research
Cancer ResearchImmunology
2018English

Oncolytic Virotherapy for Human Malignant Mesothelioma: Recent Advances

Oncolytic Virotherapy
2015English

Overcoming the Limitations of Locally Administered Oncolytic Virotherapy

BMC Biomedical Engineering
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy